Jan 29, 2025 | Homepage News, News, Uncategorized
PRF is thrilled to announce that the first Progerinin clinical trial patient visits are complete! Earlier this month, we welcomed US-residents Merlin (23) and Kaylee (21) to their week-long trial visits at Boston Children’s Hospital. This groundbreaking trial...
Oct 30, 2024 | Homepage News, News, Uncategorized
So much progress, so much to share!! PRF’s 2024 newsletter is rife with exciting updates about our global work – supporting the most promising research toward better treatments and the CURE, and our strategic awareness efforts to find and help all children with...
Oct 9, 2024 | News, Uncategorized
The Progeria Research Foundation is honoring the life of our Progeria researcher and PRF spokesperson, Sammy Basso. Sammy sadly passed away at the age of 28 on October 5, 2024. Sammy was the oldest known person living with classic Progeria, which gave him a unique...
Sep 30, 2024 | Homepage News, News, Uncategorized
We’re back at it! PRF is thrilled to announce the start of a new Progeria clinical trial with a new drug called Progerinin. PRF will help fund and coordinate this trial to determine whether a new drug, called Progerinin, plus the life-extending Progeria drug...
Jul 24, 2024 | News, Uncategorized
In an article published today in the New York Times, PRF Medical Director Dr. Leslie Gordon and colleagues shared the phenomenal story of scientific collaborations that led to recent breakthroughs in genetic editing in Progeria. Partnerships with PRF’s long-time...
May 4, 2024 | News, Uncategorized
Effective Friday, May 3rd, 2024, Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd, has acquired global rights to lonafarnib (Zokinvy) from Eiger BioPharmaceuticals (Eiger). Zokinvy® is provided to...
English 
Arabic 
Bengali 
Chinese 
Dutch 
French 
German 
Hebrew 
Hindi 
Indonesian 
Italian 
Kannada 
Kazakh 
Korean 
Marathi 
Pashto 
Portuguese 
Russian 
Spanish 
Tamil 
Ukrainian 
Urdu